BioSpace News Archive

NLS Pharmaceutics Ltd., a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including narcolepsy, idiopathic hypersomnia and Kleine-Levin Syndrome and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, announced that the European Patent Office issued a Notice of Intention to Grant NLS’s patent application covering a novel formulation of mazindol for treatment of ADHD and sleep related disorders.

Pathan, one of the largest pathology laboratories in the Netherlands, has started a collaboration with Aiforia, a leading software company providing artificial intelligence (AI) solutions for medical image analysis.

Arcadia , the leading population health management and healthcare intelligence platform company, congratulates Micky Tripathi , PhD, MPP, on his new leadership role as the National Coordinator for Health Information Technology ( ONC ) with the Department of Health and Human Services (HHS). Most recently, Tripathi served as A

The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Commission (EC) has granted a marketing authorization, for ELZONRIS (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare

New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, has awarded two competitive grants to partner institutions that will bolster FARE’s 2020 expansion of the FARE Clinical Network, powering advances in food allergy research.

Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced

Dermata Therapeutics, LLC, a privately held biotechnology company focused on advanced treatments in medical and aesthetic dermatology, announced today that results from its Phase 2b study of DMT310 for the treatment of moderate to severe acne have been accepted as a poster presentation at the 2021 Maui Derm for Dermatologists Annual Conference,

XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing local tolerability data from Dermavant’s Phase 3 PSOARING pivotal trials for tapinarof